A generic version of the world’s only twice-yearly injectable drug for preventing HIV has been approved by the U.S. Food and Drug Administration, marking a significant step toward delivering affordable, rapid access to the medication across 120 low- and middle-income countries.
The pharmaceutical manufacturer released the announcement on Monday morning alongside global organizations that worked to accelerate development of the preventative treatment, lenacapavir.